These medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
Its worth being clear-eyed about the studys limits: it was a single-center, retrospective chart review, not a randomized trial, and nearly a third of patients discontinued the medication, most often due to gastrointestinal side effects
These formulations are prepared by 503A or 503B compounding pharmacies that may add supplementary ingredients based on the prescribing provider specifications
Find out what experts have recently recommended to help curb bone loss and reduce fracture risk when dieting in our updated CL Answer about supplements and diets for osteoporosis
Regulatory statements confirm there is no legal provision for BPC-157 as a pharmaceutical product or as a food or dietary supplement ingredient
10.1016/j.bbi.2016.07.143 180 MediciM